{"disease":{"id":"primary-immunodeficiency","name":"primary immunodeficiency"},"drugs":{"marketed":[{"drug_id":"human-immunoglobulin","indication_name":"Primary Humoral Immunodeficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Human immunoglobulin","company_name":"Centre Hospitalier St Anne","drug_phase":"marketed","molecular_target":"","drug_class":"Human Immunoglobulin G [EPC]","quality_score":35,"revenue":null,"mechanism":null},{"drug_id":"hyqvia","indication_name":"Primary Immunodeficiency (PI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"HyQvia","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Hyaluronic acid in subcutaneous tissue; immunoglobulin G replacement","drug_class":"Immunoglobulin replacement therapy; enzyme-facilitated subcutaneous immunoglobulin","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT03206099","title":"NIAID Centralized Sequencing Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03610802","title":"Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03394053","title":"The Mechanistic Biology of Primary Immunodeficiency Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03815357","title":"What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?","phase":"","overall_status":"COMPLETED","enrollment_count":380,"lead_sponsor_name":"Murdoch Childrens Research Institute","has_results":false},{"nct_id":"NCT02579967","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":354,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02303093","title":"Non-Interventional Study on the Tolerability and Efficacy of IVIG","phase":"","overall_status":"COMPLETED","enrollment_count":344,"lead_sponsor_name":"Octapharma","has_results":true},{"nct_id":"NCT04864886","title":"Metabolic Profiling of Immune Responses in Immune-mediated Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02593188","title":"Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)","phase":"","overall_status":"COMPLETED","enrollment_count":264,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT00895271","title":"Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":200,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05758506","title":"Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"PATH","has_results":false},{"nct_id":"NCT03188419","title":"Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide","phase":"","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03054181","title":"Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)","phase":"","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"GWT-TUD GmbH","has_results":false},{"nct_id":"NCT03716700","title":"Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT06659588","title":"Study of Populations at Risk of Developing Chronic Hepatitis Linked to Chronic Enteric Virus Infection in Patients With Primary Immunodeficiency and Secondary Humoral Deficiency","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04724642","title":"COVID-19 Vaccine in Patients After Allogeneic HCT, CAR-T Therapy and With Primary Immune Deficiency","phase":"","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT05321407","title":"COVID-19 Vaccine Responses in PIDD Subjects","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06565078","title":"A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05986734","title":"Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","has_results":false},{"nct_id":"NCT01529827","title":"Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04356053","title":"Systematic Screening for Primary Immunodeficiencies in Patients Hospitalized for Severe Infections in Intensive Care.","phase":"","overall_status":"UNKNOWN","enrollment_count":90,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT00814320","title":"Gammagard Liquid and rHuPH20 in PID","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":89,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT01218438","title":"Phase 2/3 Study of IGSC, 20% in PIDD","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT02269163","title":"Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":82,"lead_sponsor_name":"Prometic Biotherapeutics, Inc.","has_results":true},{"nct_id":"NCT02810444","title":"Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":81,"lead_sponsor_name":"Biotest","has_results":true},{"nct_id":"NCT03576742","title":"Severe Immune Cytopenia Registry Www.Sic-reg.Org","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Medical University of Graz","has_results":false},{"nct_id":"NCT03663933","title":"Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":71,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04339777","title":"Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":66,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01175213","title":"Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT05755035","title":"A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00157079","title":"Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT06649643","title":"Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT07346859","title":"Study of BP-SCIG 20% in Patients With Primary Immunodeficiency (PID)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Biopharma Plasma LLC","has_results":false},{"nct_id":"NCT01412385","title":"Immune Globulin Subcutaenous (Human), 20%","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT01485796","title":"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT06076642","title":"A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":53,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT06150833","title":"Efficacy and Safety and Pharmacokinetics of Boya IVIG","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Azidus Brasil","has_results":false},{"nct_id":"NCT04528355","title":"Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Paul Szabolcs","has_results":false},{"nct_id":"NCT05621876","title":"Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"PATH","has_results":false},{"nct_id":"NCT07262047","title":"Quality of Life Among Children With Inborn Error of Immunity","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Sohag University","has_results":false},{"nct_id":"NCT00546871","title":"Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT03033745","title":"Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"CSL Behring","has_results":true},{"nct_id":"NCT04691622","title":"Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Children's National Research Institute","has_results":false},{"nct_id":"NCT03961009","title":"Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Kedrion S.p.A.","has_results":true},{"nct_id":"NCT06355323","title":"Bronchiectasis Prevalence in Patients With Primary Humoral Immunodefiency in Champagne-Ardenne Region, France","phase":"NA","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT01581593","title":"Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Kedrion S.p.A.","has_results":true},{"nct_id":"NCT07017036","title":"Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Virchow Group","has_results":false},{"nct_id":"NCT03277313","title":"Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT03116347","title":"Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Baxalta now part of Shire","has_results":true},{"nct_id":"NCT06092528","title":"Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency","phase":"NA","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Gazi University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}